



SCITopic

## Aleksi Šedo: We are introducing two new Ph.D. programmes

We are pleased to announce two groundbreaking doctoral study programmes, Molecular and Translational Medicine at the Palacky University (Olomouc node) and Experimental and Clinical Oncology at Charles University (Prague node), which were established in partnership with and under the patronage of the NICR. nModern medicine takes place mainly on the molecular level, what drives medicine forward is its biomedical component, and that is a mostly multidisciplinary field. That is

why in connection with our new doctoral programmes we do not speak only of physicians or natural scientists. We want to train professionals whose work integrates both of these elements and who will determine the future direction of our disciplines', explains Aleksi Šedo, director of the NICR.

[Learn more](#)

SCIGeneration



### Lenka Bešše: I appreciate the opportunity of studying abroad

'Inclusion of molecular medicine into the portfolio of Ph.D. programmes is nowadays in high demand. Given the growing awareness of the genetic and molecular foundation of various diseases, it is important that future scientists have access to instruction and research in this area. What I perceive as positive are for instance the opportunities to study these subjects abroad: they can help us learn about the current questions that molecular medicine is trying to answer and thereby also the issues we should study in our laboratories.'

[Learn more](#)



### Pavel Bouchal: The ideal Ph.D. programme is multidisciplinary

'A qualified researcher must master many sophisticated laboratory methods and related data analysis approaches but also understand the perspective of colleagues from other fields of expertise. From the position of the first or corresponding author of a publication, the researcher must be able to explain everything smoothly and awlessly. A multidisciplinary Ph.D. programme is thus the ideal school for acquiring knowledge and establishing contacts, to some extent, it may also serve as a platform for scientific collaboration.'

[Learn more](#)

SCIPapers

#### Critical appraisal of the piRNA-PIWI axis in cancer and cancer stem cells

Elena Garcia-Borja, Frantisek Siegl, Rosana Mateu et al.

Biomark Res. 2024 February

DOI: 10.1186/s40364-024-00563-3

PMID: 38303021

#### Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer

Anna Vyhliđalová Kotrbová, Kristína G6m6ryova, Ant6nia Mikulova et al.

J Extracell Vesicles. 2024 March

DOI: 10.1002/jev2.12420

PMID: 38490958

#### De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors

Tomas Hornak, Jiri Mayer, Petra Ciatkova et al.

Am J Hematol. 2024 April

DOI: 10.1002/ajh.27229

PMID: 38317312

SCICommunity



### A New Research Team Targets Tumours Associated with HPV


'Our group is active in several areas but at this point, we are focusing on oropharyngeal

cancers, especially those associated with HPV infection. Unlike in the case of cervical cancers, there is no routine screening for their early detection. As a result, while we see a decrease in the number of new cases of cervical cancer in the population, the incidence of HPV-associated oropharyngeal cancers is increasing year on year and is a real problem. Therefore, we have developed a 'gargling test' that would enable easy collection of biological material from the oral cavity', says Vladimira Koudelakova, head of a research group created in 2023 in the Node Olomouc of the NICR at the Institute of Molecular and Translational Medicine of the Faculty of Medicine and Dentistry of Palacky University.

[Learn more](#)

SCITidbits

## Can you tell who this is?



### Take a look tomorrow at



Share with us untraditional pictures from your lab!

SCIProgramme

### RP4 for Early Detection and Prevention

'The development of more accurate and accessible methods of early diagnostics will enable us to detect cancers at treatable stages, while the identification of individuals who are at an increased genetic risk opens the way to personalised preventive programmes.'

Our results can help shift the options for prevention and personalised care to a new level, improve quality of life, and lower the social and economic impact of tumours', say Petr Džubak and Marek Svoboda, heads of Early Detection and Prevention of Cancers, one of the research directions of NICR, when introducing their programme.

[Learn more](#)

SCIIndicators

### Indicators are not just publications...

One of the nonpublication indicators that based on which NICR is assessed is the participation of members of the research team in international professional networks, R&D organisations, and foreign evaluation panels and committees.

The fact that we are doing relatively well indicates that, in the NICR, we have many colleagues with more than just national reach and renown!

[Learn more](#)

SCIMedia

### Sabotage in Cellular Powerhouses: A Promising Czech Concept for Cancer Therapy

Medical Tribune, April 12, 2024  
Jiřı Neužil's team at the Prague node had synthesised a mitochondria-targeting TPP+ labeled tamoxifen, so far the only drug of this kind in clinical research worldwide.

### Are We Going to Defeat Cancer?

Czech TV, Bilance (programme), March 6, 2024  
Filming took place also at the Prague and Brno institutes involved in the NICR.

### Cancer, Research and Proteases

TALK TV, Jadrna veda (podcast), March 26, 2024  
Scientific publicist Leoš Kyša interviewed Petr Bušek and Ivan Melezınek from First Faculty of Medicine, Charles University.

SCICalendar

#### ONKO PACIENT

30 May 2024

Brožík Hall, Old Town Hall, Prague

Second patient conference focused on hormone-dependent cancers, such as breast or prostate cancer.

#### Summer School on Tumor Microenvironment and Immunity

26–29 June 2024

Nove Hrady

This event is aimed at doctoral students and recent doctoral graduates. Programme includes lectures and a hands-on ELISPOT minicourse.

#### Czech Annual Cancer Research Meeting

18–20 November 2024

#### NH COLLECTION OLOMOUC CONGRESS

Call for speakers! Nominate yourself or a colleague to give a future presentation at the meeting.